Imbio and GE Healthcare Collaborate to Enable Lung Density Analysis™ Within GE Health Cloud Ecosystem
Imbio and GE Healthcare to support more personalized CT lung diagnosis with quantifiable clinical insights
MINNEAPOLIS, March 21, 2016 /PRNewswire/ -- Imbio, a leader in fully automated, biomarker-based solutions for quantitative Lung imaging, and GE Healthcare are pleased to announce a collaboration to make Imbio's Lung Density Analysis™, a volumetric imaging solution for Lung CT, one of the first software applications to be available in the GE Health Cloud.
As a result of this collaboration, Lung Density Analysis (LDA), Imbio's FDA cleared and CE marked software for quantification and visualization of COPD components, will be fully integrated into GE Health Cloud's clinical workflow. Customers subscribing to LDA through GE Health Cloud will have their CT lung images automatically uploaded for processing with LDA, to receive both an augmented CT lung series with density overlays for detailed image interpretation, as well as patient-friendly summary reports added to their study results. The full workflow integration will enable streamlined processing to quantify and localize areas of low lung density and air trapping, providing physicians with fast, secure and seamless clinical information to help deliver better patient care. This agreement marks the first step in integrating Imbio's portfolio of lung analysis solutions into the GE Health Cloud.
"At Imbio, we are working to break down the barriers to broader use of clinically valuable quantitative imaging," commented Cynthia Maier, Imbio's CEO. "Partnering with GE to bring Lung Density Analysis to the GE Health Cloud is directly aligned with our focus on fully-automated applications to improve productivity, while making richer, personalized patient analysis accessible to all physicians to aid their diagnosis and care planning."
"This partnership with Imbio confirms our commitment to providing healthcare professionals with enhanced quantifiable clinical insights. By incorporating Imbio's personalized lung analysis into GE Healthcare's cloud-enabled workflow solutions, we are enriching the data that we can provide through the GE Health Cloud," said Evren Eryurek, Software Chief Technology Officer for GE Healthcare.
Lung Density Analysis™ is expected to be released on the GE Health Cloud when it launches in mid-2016.
About GE Healthcare
GE Healthcare provides transformational medical technologies and services to meet the demand for increased access, enhanced quality and more affordable healthcare around the world. GE (NYSE: GE) works on things that matter - great people and technologies taking on tough challenges. From medical imaging, software & IT, patient monitoring and diagnostics to drug discovery, biopharmaceutical manufacturing technologies and performance improvement solutions, GE Healthcare helps medical professionals deliver great healthcare to their patients. For more information about GE Healthcare, visit our website at http://www.gehealthcare.com.
About Imbio
Imbio is transforming medical image analysis by making breakthrough Radiology diagnostics accessible and affordable for all physicians. Imbio offers quantitative biomarker analyses that are fully automated to preserve physicians' time while providing data and visualization to help make better personalized patient care decisions. With flexible Cloud and Enterprise SaaS solutions, Imbio makes advanced image analysis accessible to all healthcare providers. Imbio's FDA cleared and CE marked Lung Density Analysis™ is part of the company's portfolio of imaging solutions for chronic lung diseases. For more information, please visit www.imbio.com.
Logo - http://photos.prnewswire.com/prnh/20160318/345767LOGO
SOURCE Imbio
Share this article